Dupixent® (dupilumab) Late-breaking Phase 3 COPD Result

Dupixent® (dupilumab) Late-breaking Phase 3 COPD Results Presented at ATS and Simultaneously Published in the New England Journal of Medicine

Dupixent® (dupilumab) Late-breaking Phase 3 COPD Results Presented at ATS and Simultaneously Published in the New England Journal of Medicine
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

United States , Japan , Paris , France General , France , American , Regeneron Velocimmune Technologyregeneron , Georged Yancopoulos , Surya Bhatt , Clinical Research Programregeneron , Exchange Commission , Dupilumab Development Programdupilumab , Twitter , Trial Program , Pulmonary Research , Nasdaq , Regeneron Pharmaceuticals Inc , International Conference , American Thoracic Society , Regeneron Genetics Center , Euronext , Dupixent Phase , Thoracic Society , England Journal , Recently Published Pulmonary , New England Journal , Clinical Trial Results , Associate Professor , Birmingham Division , Critical Care Medicine , Respiratory Questionnaire , Evaluating Respiratory Symptoms , Velocimmune Technologyregeneron , Chief Scientific Officer George , Development Programdupilumab , Forward Looking Statements , Digital Mediathis , Regeneron Pharmaceuticals , Product Candidates , Forward Looking Statementsthis , Private Securities Litigation Reform Act , Statement Regarding Forward Looking ,